The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
IKZF1plusDefines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
Open accessAbstract
Purpose: Somatic deletions that affect the lymphoid transcription factor–coding gene IKZF1 have previously been reported as independently associated with a poor prognosis in pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). We have now refined the prognostic strength of IKZF1 deletions by analyzing the effect of co-occurring deletions. Patients and Methods: The analysis involved 991 patients with BCP ALL treated in the Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL 2000 trial with complete information for copy number alterations of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, Xp22.33/Yp11.31 (PAR1 region; CRLF2, CSF2RA, and IL3RA), and ERG; replication of findings involved 417 patients from the same trial. Results: IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion conferred the worst outcome and, consequently, were grouped as IKZF1 plus. The IKZF1 plus group comprised 6% of patients with BCP ALL, with a 5-year event-free survival of 53 ± 6% compared with 79 ± 5% in patients with IKZF1 deletion who did not fulfill the IKZF1 plus definition and 87 ± 1% in patients who lacked an IKZF1 deletion ( P ≤ .001). Respective 5-year cumulative relapse incidence rates were 44 ± 6%, 11 ± 4%, and 10 ± 1% ( P ≤ .001). Results were confirmed in the replication cohort, and multivariable analyses demonstrated independence of IKZF1 plus. The IKZF1 plus prognostic effect differed dramatically in analyses stratified by minimal residual disease (MRD) levels after induction treatment: 5-year event-free survival for MRD standard-risk IKZF1 plus patients was 94 ± 5% versus 40 ± 10% in MRD intermediate- and 30 ± 14% in high-risk IKZF1 plus patients ( P ≤ .001). Corresponding 5-year cumulative incidence of relapse rates were 6 ± 6%, 60 ± 10%, and 60 ± 17% ( P ≤ .001). Conclusion: IKZF1 plus describes a new MRD-dependent very-poor prognostic profile in BCP ALL. Because current AIEOP-BFM treatment is largely ineffective for MRD-positive IKZF1 plus patients, new experimental treatment approaches will be evaluated in our upcoming trial AIEOP-BFM ALL 2017.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Chronic Health Conditions in Adult Survivors of Childhood Cancer
Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa060185 · Cited by 3,597
Yeoh, E.-J., Ross, M. E., Shurtleff, S. A., Williams, W. K., Patel, D., Mahfouz, R., Behm, F. G., Raimondi, S. C., Relling, M. V., Patel, A., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00032-6 · Cited by 1,917
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan-Smith, E., Dalton, J. D., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,801
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Roberts, K. G., Li, Y., Payne-Turner, D., Harvey, R. C., Yang, Y.-L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403088 · Cited by 1,377
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Pui, C.-H., Yang, J. J., Hunger, S. P., Pieters, R., Schrappe, M., Biondi, A., Vora, A., Baruchel, A., Silverman, L. B., Schmiegelow, K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1636 · Cited by 1,007
Self-citationThe ikaros gene is required for the development of all lymphoid lineages
Georgopoulos, K., Bigby, M., Wang, J.-H., Molnar, A., Wu, P., Winandy, S., & Sharpe, A. (1994) · Cell · doi:10.1016/0092-8674(94)90407-3 · Cited by 985
Conter, V., Bartram, C. R., Valsecchi, M. G., Schrauder, A., Panzer-Grümayer, R., Möricke, A., Aricò, M., Zimmermann, M., Mann, G., De Rossi, G., et al. (2010) · Blood · doi:10.1182/blood-2009-10-248146 · Cited by 785
Self-citationJAK mutations in high-risk childhood acute lymphoblastic leukemia
Mullighan, C. G., Zhang, J., Harvey, R. C., Collins-Underwood, J. R., Schulman, B. A., Phillips, L. A., Tasian, S. K., Loh, M. L., Su, X., Liu, W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811761106 · Cited by 562
Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., & Richards, S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70600-9 · Cited by 478
Martinelli, G., Iacobucci, I., Storlazzi, C. T., Vignetti, M., Paoloni, F., Cilloni, D., Soverini, S., Vitale, A., Chiaretti, S., Cimino, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6408 · Cited by 317
Perez-Andreu, V., Roberts, K. G., Harvey, R. C., Yang, W., Cheng, C., Pei, D., Xu, H., Gastier-Foster, J., E, S., Lim, J. Y.-S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2803 · Cited by 305
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine
Hunger, S. P., & Mullighan, C. G. (2015) · Blood · doi:10.1182/blood-2015-02-580043 · Cited by 292
van der Veer, A., Waanders, E., Pieters, R., Willemse, M. E., Van Reijmersdal, S. V., Russell, L. J., Harrison, C. J., Evans, W. E., van der Velden, V. H. J., Hoogerbrugge, P. M., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462358 · Cited by 289
Möricke, A., Zimmermann, M., Valsecchi, M. G., Stanulla, M., Biondi, A., Mann, G., Locatelli, F., Cazzaniga, G., Niggli, F., Aricò, M., et al. (2016) · Blood · doi:10.1182/blood-2015-09-670729 · Cited by 283
Self-citationIKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL
Kuiper, R. P., Waanders, E., van der Velden, V. H. J., van Reijmersdal, S. V., Venkatachalam, R., Scheijen, B., Sonneveld, E., van Dongen, J. J. M., Veerman, A. J. P., van Leeuwen, F. N., et al. (2010) · Leukemia · doi:10.1038/leu.2010.87 · Cited by 268
Fischer, U., Forster, M., Rinaldi, A., Risch, T., Sungalee, S., Warnatz, H.-J., Bornhauser, B., Gombert, M., Kratsch, C., Stütz, A. M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3362 · Cited by 257
Self-citationIrving, J., Matheson, E., Minto, L., Blair, H., Case, M., Halsey, C., Swidenbank, I., Ponthan, F., Kirschner-Schwabe, R., Groeneveld-Krentz, S., et al. (2014) · Blood · doi:10.1182/blood-2014-04-531871 · Cited by 254
Self-citationChen, I.-M., Harvey, R. C., Mullighan, C. G., Gastier-Foster, J., Wharton, W., Kang, H., Borowitz, M. J., Camitta, B. M., Carroll, A. J., Devidas, M., et al. (2012) · Blood · doi:10.1182/blood-2011-11-394221 · Cited by 245
Moorman, A. V., Richards, S. M., Robinson, H. M., Strefford, J. C., Gibson, B. E. S., Kinsey, S. E., Eden, T. O. B., Vora, A. J., Mitchell, C. D., Harrison, C. J., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040436 · Cited by 222
Moorman, A. V., Enshaei, A., Schwab, C., Wade, R., Chilton, L., Elliott, A., Richardson, S., Hancock, J., Kinsey, S. E., Mitchell, C. D., et al. (2014) · Blood · doi:10.1182/blood-2014-03-562918 · Cited by 215
The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia
Paulsson, K., Lilljebjörn, H., Biloglav, A., Olsson, L., Rissler, M., Castor, A., Barbany, G., Fogelstrand, L., Nordgren, A., Sjögren, H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3301 · Cited by 198
Loh, M. L., Zhang, J., Harvey, R. C., Roberts, K., Payne-Turner, D., Kang, H., Wu, G., Chen, X., Becksfort, J., Edmonson, M., et al. (2013) · Blood · doi:10.1182/blood-2012-04-422691 · Cited by 177
Monoclonal antibodies in acute lymphoblastic leukemia
Jabbour, E., O’Brien, S., Ravandi, F., & Kantarjian, H. (2015) · Blood · doi:10.1182/blood-2014-08-596403 · Cited by 162
Clappier, E., Mf, A., Rapion, J., Bakkus, M. H. C., Caye‐Eude, A., Khemiri, A., Giroux, C., Hernandez, L., Kabongo, E., Savola, S. P., et al. (2013) · Leukemia · doi:10.1038/leu.2013.277 · Cited by 162
Self-citationDorge, P., Meissner, B., Zimmermann, M., Moricke, A., Schrauder, A., Bouquin, J.-P., Schewe, D., Harbott, J., Teigler-Schlegel, A., Ratei, R., et al. (2013) · Haematologica · doi:10.3324/haematol.2011.056135 · Cited by 162
Self-citationMigliorini, G., Fiege, B., Hosking, F. J., Ma, Y., Kumar, R., Sherborne, A. L., da Silva Filho, M. I., Vijayakrishnan, J., Koehler, R., Thomsen, H., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491316 · Cited by 160
Self-citationLugthart, S., Cheok, M. H., den Boer, M. L., Yang, W., Holleman, A., Cheng, C., Pui, C.-H., Relling, M. V., Janka-Schaub, G. E., Pieters, R., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.002 · Cited by 160
IKZF1 status as a prognostic feature in BCR-ABL1–positive childhood ALL
van der Veer, A., Zaliova, M. K., Mottadelli, F., Lorenzo, P. D., Kronnie, G. T., Harrison, C. J., Cavé, H., Trka, J., Saha, V., Schrappe, M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-509794 · Cited by 156
Self-citationRisk factors for treatment related mortality in childhood acute lymphoblastic leukaemia
Lund, B., Åsberg, A. E., Heyman, M. M., Kanerva, J. A., Harila‐Saari, A. H., Hasle, H., Söderhäll, S., Jónsson, Ó. G., Lydersen, S., Schmiegelow, K., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22719 · Cited by 142
Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances
Vrooman, L. M., & Silverman, L. B. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0337-y · Cited by 136
Waanders, E., van der Velden, V. H. J., van der Schoot, C. E., van Leeuwen, F. N., van Reijmersdal, S. V., de Haas, V., Veerman, A. J. P., van Kessel, A. G., Hoogerbrugge, P. M., Kuiper, R. P., et al. (2010) · Leukemia · doi:10.1038/leu.2010.275 · Cited by 130
Clappier, E., Grardel, N., Bakkus, M. H. C., Rapion, J., Moerloose, B. D., Kastner, P., Caye‐Eude, A., Vivent, J., Costa, V., Ferster, A., et al. (2015) · Leukemia · doi:10.1038/leu.2015.134 · Cited by 105
Self-citationStrefford, J. C., Worley, H., Barber, K. E., Wright, S. L., Stewart, A. R. M., Robinson, H. M., Bettney, G., van Delft, F. W., Atherton, M., Davies, T., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210190 · Cited by 103
Zaliova, M. K., Zimmermannová, O., Dörge, P., Eckert, C., Möricke, A., Zimmermann, M., Stuchlý, J., Teigler‐Schlegel, A., Meissner, B., Koehler, R., et al. (2013) · Leukemia · doi:10.1038/leu.2013.282 · Cited by 96
Self-citationDavidsson, J., Paulsson, K. M., Lindgren, D., Lilljebjörn, H., Chaplin, T., Forestier, E., Andersen, M. K., Nordgren, A., Rosenquist, R., Fioretos, T., et al. (2010) · Leukemia · doi:10.1038/leu.2010.39 · Cited by 78
Palmi, C., Valsecchi, M. G., Longinotti, G., Silvestri, D., Carrino, V., Conter, V., Basso, G., Biondi, A., Kronnie, G. T., & Cazzaniga, G. (2013) · Haematologica · doi:10.3324/haematol.2012.075432 · Cited by 72
Self-citationYamashita, Y. I., Shimada, A., Yamada, T., Yamaji, K., Hori, T., Tsurusawa, M., Watanabe, A., Kikuta, A., Asami, K., Saito, A. M., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24571 · Cited by 68
Olsson, L., Castor, A., Behrendtz, M., Biloglav, A., Forestier, E., Paulsson, K. M., & Johansson, B. (2013) · Leukemia · doi:10.1038/leu.2013.206 · Cited by 67
Öfverholm, I. I., Tran, A. N., Heyman, M. M., Zachariadis, V., Nordenskjöld, M., Nordgren, A., & Barbany, G. (2013) · Leukemia · doi:10.1038/leu.2013.92 · Cited by 54
Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia
Chiaretti, S., Gianfelici, V., O'Brien, S. M., & Mullighan, C. G. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156628 · Cited by 45
Schmoor, C., Ulm, K., & Schumacher, M. C. (1993) · Statistics in Medicine · doi:10.1002/sim.4780122411 · Cited by 41
Hinze, L., Möricke, A., Zimmermann, M., Junk, S. V., Cario, G., Dağdan, E., Kratz, C. P., Conter, V., Schrappe, M., & Stanulla, M. (2017) · Leukemia · doi:10.1038/leu.2017.154 · Cited by 25
Self-citationOlsson, L., Albitar, F. S., Castor, A., Behrendtz, M., Biloglav, A., Paulsson, K. M., & Johansson, B. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22245 · Cited by 23
Cited by
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
Pediatric acute lymphoblastic leukemia
Inaba, H., & Mullighan, C. G. (2020) · Haematologica · doi:10.3324/haematol.2020.247031 · Cited by 696
The genomic landscape of pediatric acute lymphoblastic leukemia
Brady, S. W., Roberts, K. G., Gu, Z., Shi, L., Pounds, S., Pei, D., Cheng, C., Dai, Y., Devidas, M., Qu, C., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01159-z · Cited by 391
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
Teachey, D. T., & Pui, C.-H. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30031-2 · Cited by 291
Metadata
- Authors
- Stanulla, M., Dagdan, E., Zaliova, M., Möricke, A., Palmi, C., Cazzaniga, G., Eckert, C., te Kronnie, G., Bourquin, J.-P., Bornhauser, B., Koehler, R., Bartram, C. R., Ludwig, W.-D., Bleckmann, K., Groeneveld-Krentz, S., Schewe, D., Junk, S. V., Hinze, L., Klein, N., Kratz, C. P., Biondi, A., Borkhardt, A., Kulozik, A., Muckenthaler, M. U., Basso, G., Valsecchi, M. G., Izraeli, S., Petersen, B.-S., Franke, A., Dörge, P., Steinemann, D., Haas, O. A., Panzer-Grümayer, R., Cavé, H., Houlston, R. S., Cario, G., Schrappe, M., Zimmermann, M., for the TRANSCALL Consortium, & the International BFM Study Group
- Venue
- Journal of Clinical Oncology
- Published
- 2018-04-20
- Volume
- 36
- Issue
- 12
- Pages
- 1240-1249
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2794056739
- Cited by
- 303
- References
- 49
- FWCI
- 26.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.